Analysts’ Recent Ratings Updates for Legend Biotech (LEGN)

A number of research firms have changed their ratings and price targets for Legend Biotech (NASDAQ: LEGN):

• 8/12/2026 – Legend Biotech had its price target raised by Morgan Stanley from $48.00 to $49.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Legend Biotech was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”. They now have a $40.00 price target on the stock, down from $75.00.
• 8/12/2026 – Legend Biotech had its price target lowered by Barclays PLC from $80.00 to $78.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Legend Biotech had its price target lowered by TD Cowen from $29.00 to $24.00. They now have a “hold” rating on the stock.
• 8/12/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $59.00 to $58.00. They now have an “outperform” rating on the stock.
• 8/12/2026 – Legend Biotech had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $40.00 price target on the stock, down from $75.00.
• 7/30/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/28/2026 – Legend Biotech had its “buy” rating reaffirmed by Benchmark Co..
• 7/28/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 7/27/2026 – Legend Biotech had its “neutral” rating reaffirmed by UBS Group AG. They now have a $28.00 price target on the stock, down from $49.00.
• 7/27/2026 – Legend Biotech had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $58.00 price target on the stock.
• 7/27/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $63.00 to $59.00. They now have an “outperform” rating on the stock.
• 7/24/2026 – Legend Biotech was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $28.00 price target on the stock, down from $49.00.
• 7/16/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright.
• 7/13/2026 – Legend Biotech is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $35.00 price target on the stock.
• 7/10/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/7/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $64.00 to $63.00. They now have an “outperform” rating on the stock.
• 6/24/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insiders Place Their Bets

In other Legend Biotech news, CEO Ying Huang sold 5,566 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $14.78, for a total value of $82,265.48. Following the transaction, the chief executive officer owned 241,872 shares of the company’s stock, valued at approximately $3,574,868.16. This represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.02% of the company’s stock.

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.